IL133136A0 - Use of leptin antagonists for the treatment of diabetes - Google Patents

Use of leptin antagonists for the treatment of diabetes

Info

Publication number
IL133136A0
IL133136A0 IL13313697A IL13313697A IL133136A0 IL 133136 A0 IL133136 A0 IL 133136A0 IL 13313697 A IL13313697 A IL 13313697A IL 13313697 A IL13313697 A IL 13313697A IL 133136 A0 IL133136 A0 IL 133136A0
Authority
IL
Israel
Prior art keywords
diabetes
treatment
leptin antagonists
leptin
antagonists
Prior art date
Application number
IL13313697A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133136A0 publication Critical patent/IL133136A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13313697A 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes IL133136A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (fr) 1997-06-06 1997-06-06 Utilisation d'antagonistes de leptine pour traiter le diabete

Publications (1)

Publication Number Publication Date
IL133136A0 true IL133136A0 (en) 2001-03-19

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13313697A IL133136A0 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Country Status (9)

Country Link
EP (1) EP0986397A1 (fr)
JP (1) JP2002504102A (fr)
KR (1) KR20010013414A (fr)
AU (1) AU2951797A (fr)
CA (1) CA2293504A1 (fr)
HU (1) HUP0003428A3 (fr)
IL (1) IL133136A0 (fr)
TR (1) TR199902980T2 (fr)
WO (1) WO1998055139A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN103897066A (zh) 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (fr) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
EA032917B1 (ru) 2010-09-28 2019-08-30 Амилин Фармасьютикалс, Ллк Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
EP2900230B1 (fr) 2012-09-27 2018-08-15 The Children's Medical Center Corporation Composés pour le traitement de l'obésité et méthodes d'utilisation de ceux-ci
ES2709976T3 (es) 2013-11-26 2019-04-22 Childrens Medical Ct Corp Compuestos para el tratamiento de la obesidad y procedimientos de uso de los mismos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3036551A1 (fr) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Procedes de detection d'anticorps neutralisants anti-leptine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH11508895A (ja) * 1995-06-30 1999-08-03 イーライ・リリー・アンド・カンパニー 糖尿病を処置する方法

Also Published As

Publication number Publication date
WO1998055139A1 (fr) 1998-12-10
AU2951797A (en) 1998-12-21
KR20010013414A (fr) 2001-02-26
CA2293504A1 (fr) 1998-12-10
TR199902980T2 (xx) 2000-05-22
JP2002504102A (ja) 2002-02-05
EP0986397A1 (fr) 2000-03-22
HUP0003428A3 (en) 2001-12-28
HUP0003428A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
IL130027A (en) Rosiglitazone - glyburide synergistic combinations for treatment of diabetes
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
HUP0002030A3 (en) Use of glur5 receptorantagonists for the treatment of pain
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
GB9810920D0 (en) Therapeutic use
GB9812662D0 (en) Therapeutic use
GB9816897D0 (en) Therapeutic use
GB9726223D0 (en) The treatment of materials
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
NO995940D0 (no) Anvendelse av leptin antagonister for behandling av diabetes
GB9811624D0 (en) Therapeutic use
GB9821179D0 (en) Therapeutic use
GB9812664D0 (en) Therapeutic use
PL337220A1 (en) Application of leptin antagonists in treating diabetes
GB9819505D0 (en) Heterocyclic compounds and their therapeutic use
GB9820768D0 (en) Heterocyclic compounds and their therapeutic use
GB9714742D0 (en) Medical cement
GB9713240D0 (en) Heterocyclic compounds and their therapeutic use
GB9802622D0 (en) Compounds and their therapeutic use
GB9815149D0 (en) Treatment of diabetes
GB9812314D0 (en) Treatment of diabetes
GB9812661D0 (en) Therapeutic use
GB9812612D0 (en) Therapeutic use
GB9801581D0 (en) Therapeutic use